Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Rotigotine in RLS
NCT00263068Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in restless legs syndrome (RLS), sponsored by UCB. Primary endpoint: Safety and Tolerability at 1 year. Started Dec 2005; status: completed.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00263068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263068.